Hims & Hers Health delivered one of the more complicated earnings reactions in the digital health sector: the company missed Wall Street’s first-quarter expectations and shares dropped sharply, yet several analysts still found reasons to stay constructive. For investors watching Hims & Hers stock, the debate is no longer simply about rapid revenue growth. It is about whether the company’s transition toward branded GLP-1 weight-loss drugs can support a larger, more durable business even if near-term margins come under pressure.
Seeking Alpha reported that Hims & Hers continued to attract bullish analyst commentary despite a roughly 15% stock decline after the company’s Q1 2026 results missed Street forecasts. The weak quarter was widely linked to the company’s pivot toward brand-name weight-loss medications rather than compounded versions.
That pivot is central to the investment story. Hims & Hers is trying to move from a high-growth telehealth platform with strong consumer demand into a more regulated, brand-partnered healthcare model. The shift could reduce legal and regulatory risk over time, but it also changes the company’s margin profile and forces investors to reassess earnings power.
HIMS Earnings Report: Revenue Miss, Surprise Loss and Stronger Guidance
Hims & Hers reported first-quarter revenue of $608.1 million, below the $616.85 million expected by analysts, according to LSEG data cited by Reuters. The company also posted a loss of $0.40 per share, while analysts had expected a $0.04 profit.
The headline miss explains why the market reacted negatively. Investors had been pricing Hims & Hers as a high-growth digital health company, so even a modest revenue shortfall can trigger a sharp repricing when earnings and margins also disappoint.
However, the company also raised its full-year revenue outlook. Hims & Hers now expects 2026 revenue of $2.8 billion to $3.0 billion, up from its previous forecast of $2.7 billion to $2.9 billion. Management also guided for second-quarter revenue of $680 million to $700 million, above the analyst average estimate of $642.95 million cited by Reuters.
That contrast explains why analysts are split between concern and optimism. The first-quarter numbers were weak relative to expectations, but the forward revenue guide suggests management still sees demand accelerating through the year.
Why the GLP-1 Pivot Hit Margins
The biggest issue for Hims & Hers is the company’s move away from compounded GLP-1 weight-loss drugs and toward branded products such as Novo Nordisk’s Wegovy. GLP-1 drugs are a class of medications used for diabetes and weight management; demand has surged as consumers seek medical weight-loss solutions.
Earlier this year, Hims & Hers entered a partnership with Novo Nordisk to offer Wegovy through its platform, ending a legal dispute between the companies. Reuters reported that the prior dispute followed Hims’ launch of a lower-cost compounded alternative, which the company has since stopped advertising.
This change may reduce regulatory overhang, but it also creates near-term financial pressure. Branded drugs can carry different economics than compounded versions, and Hims & Hers is absorbing restructuring costs as it adjusts the business. Reuters reported that the company’s Q1 loss was tied to write-downs on semaglutide compounding ingredients, one-time legal costs and merger expenses.
For investors, this is the key trade-off. The branded GLP-1 model may be more sustainable from a compliance and partnership perspective, but it may also be less profitable in the short run. That is why Hims & Hers stock sold off even as the company raised revenue guidance.
Analyst Views: Why the Pullback Still Has Bulls
Despite the earnings miss, some analysts continue to see a path for Hims & Hers stock to recover. Seeking Alpha noted that bullish views persisted after the Q1 report, with some analysts arguing that the market may be underestimating future benefits from the company’s business pivot.
Reuters reported that J.P. Morgan described the quarter as “no worse than feared,” while analyst Cory Carpenter pointed to a more stable weight-loss business, potential peptide legalization and revenue reacceleration in the second half as possible catalysts.
Jefferies analyst Brian Tanquilut took a more measured view, saying HIMS is now an “execution story” and that investors want evidence that earnings power has bottomed before driving the stock significantly higher.
That framing is useful. Hims & Hers may still have a strong consumer health platform, but the stock now needs proof. Investors will likely demand evidence that revenue growth can translate into operating leverage, not just higher sales at lower margins.
Subscriber Growth and Revenue Quality Matter Now
Hims & Hers ended the quarter with nearly 2.6 million subscribers, up 9% year over year, according to the company’s Q1 release. Revenue rose 4% year over year to approximately $608 million, while the company raised its full-year revenue guidance and updated adjusted EBITDA guidance to $275 million to $350 million.
Subscriber growth remains a positive signal. A larger member base gives Hims & Hers more opportunities to cross-sell products in sexual health, dermatology, mental health, hair loss, hormone care and weight management. The long-term bull case depends on whether the company can deepen relationships with customers and expand into higher-value healthcare categories.
But revenue quality is now just as important as revenue growth. Monthly revenue per average subscriber fell to $80 from $85 a year earlier, according to Reuters. That decline raises questions about pricing, product mix and customer monetization.
A digital health platform can grow users and still disappoint investors if each user generates less revenue or lower gross profit. That is why the next few quarters will be important for HIMS stock. Investors will want to see whether GLP-1 demand brings in customers who stay on the platform and adopt additional services.
What Hims & Hers Stock Investors Should Watch Next
The most important question is whether the GLP-1 transition is a temporary margin reset or a structural reduction in profitability. If the Novo Nordisk partnership brings in a large number of new users and supports broader healthcare engagement, the near-term pain could prove manageable. If branded drug economics permanently compress margins, the valuation debate becomes more difficult.
Investors should watch four areas in upcoming HIMS earnings reports: revenue growth, adjusted EBITDA margin, subscriber growth and monthly revenue per average subscriber. Management commentary on GLP-1 demand, peptide products and international expansion will also matter.
Regulation is another key factor. The FDA’s tightening stance on copycat GLP-1 compounding has already influenced the company’s strategy, and future policy shifts could shape how Hims & Hers competes in weight-loss medications. Reuters reported that the company is also watching potential regulatory changes around peptide access, which management has described as another possible growth area.
For now, Hims & Hers stock sits at a crossroads. The company has a large consumer platform, a growing subscriber base and a clearer branded-drug pathway. It also has lower near-term profitability, softer revenue per subscriber and a business model in transition. The bullish case is still alive, but it now depends more heavily on execution than momentum.
FAQ
Why did Hims & Hers stock fall after Q1 earnings?
Hims & Hers stock fell after the company missed first-quarter revenue expectations and reported a surprise loss. Investors were also concerned about margin pressure from the shift toward branded GLP-1 drugs.
What were Hims & Hers Q1 2026 results?
Hims & Hers reported Q1 revenue of $608.1 million, below analyst expectations of $616.85 million, and a loss of $0.40 per share versus expectations for a $0.04 profit.
Why are some analysts still bullish on HIMS stock?
Some analysts believe the market may be overlooking future benefits from a more stable weight-loss business, the Novo Nordisk partnership, potential peptide products and stronger revenue growth later in 2026.
What is the biggest risk for Hims & Hers investors?
The biggest risk is that the shift from compounded GLP-1 drugs to branded medications could permanently lower margins, even if revenue continues to grow.
What should investors watch in the next HIMS earnings report?
Investors should monitor revenue growth, adjusted EBITDA margins, subscriber trends, revenue per subscriber and management’s commentary on GLP-1 demand and regulatory developments.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always conduct your own research before making any investment decisions.
